JLE

e-VEGF-IMMUNO-actu

MENU

Pro-angiogéniques : de nouveaux alliés de la chimiothérapie ? Volume 10, numéro 1, Mai 2015

  • [1] Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605-22.
  • [2] Batchelor TT, Gerstner ER, Emblem KE. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA. 2013;110:19059-64.
  • [3] Franco M, Man S, Chen L. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006;66:3639-48.
  • [4] Wong PP, Demircioglu F, Ghazaly E. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell. 2015;27:123-137.
  • [5] Reynolds AR, Hart IR, Watson AR. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392-400.